Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have advanced solid tumour cancer of any type (Phase I of the trial) or advanced prostate cancer with a PSA level of at least 0.1 ng/mL (Phase II of the trial)
• People whose cancer diagnosis has been confirmed by a pathology report or documented clinical note
• People whose cancer can be measured or tracked through scans, blood tests, or specialised imaging
• People who have given voluntary, signed, and dated consent on a form approved by the relevant review board
• People whose cancer has continued to grow or spread despite receiving one or more standard treatments, such as chemotherapy, hormone therapy, radiation, surgery, immunotherapy, or cell therapy
• People aged 18 years or older
• People with a general health and activity level rated 0, 1, or 2 on the ECOG scale, meaning they are able to carry out at least some daily activities independently (confirm with trial site)
• People whose liver function blood test results are within the ranges required by the trial, including specific allowances for people with a condition called Gilbert's syndrome (confirm with trial site)
• People whose kidney function blood test results are within the range required by the trial (confirm with trial site)
• People whose blood cell counts — including white blood cells, platelets, and haemoglobin — meet the minimum levels required by the trial (confirm with trial site)
• People whose blood sugar levels fall within the acceptable range for this trial, whether fasting or non-fasting (confirm with trial site)
• People whose urine test results show no significant abnormalities
• People whose blood pressure is adequately controlled, as determined by the treating doctor
• People who are capable of having children and who agree to use effective contraception for the duration of the trial
• People who need narcotic pain medication and have been on a stable dose for at least 2 weeks before joining the trial
• People being considered for a treatment dose that includes a drug called nelfinavir mesylate must stop taking any statin medications at least 48 hours before starting trial treatment

Who may not be able to join:

• People with serious heart conditions, including severe heart failure (New York Heart Association Class III or IV), a heart attack in the past 6 months, an unstable heart rhythm, or a history of reduced blood flow to the heart shown on a heart trace (ECG)
• People who have been hospitalised for a psychiatric condition within the last two years
• People with a significant neurological condition such as Parkinson's disease, dementia, or multiple sclerosis, as assessed by the enrolling doctor
• People who have an active, uncontrolled infection (bacterial, viral, or fungal) that requires systemic treatment
• People who have received radiation therapy, surgery, or another investigational treatment within 28 days before registering for the trial
• People who are unwilling or unable to follow the procedures required by the trial
• People with a serious non-cancer illness that the investigator believes could interfere with the trial's goals
• People who are currently taking blood-thinning medications including coumadin (warfarin), apixaban, argatroban, or rivaroxaban
• People who are currently taking part in another clinical trial of an investigational product
• People with any other mental health condition that the enrolling doctor determines would prevent safe participation in the trial
• People who are prisoners or who are involuntarily detained for treatment of a psychiatric or physical illness

Important: Always verify eligibility with the trial site directly before applying.